|
|
|
| Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide and sorafenib in liver cancer cells |
| Lin-Ping Cao a , b , Chen Zhang a , b , Xiao-Yu Weng a , b , Hai-Yang Xie a , b , c , Jian Wu a , b , c , Shu-Sen Zheng a , b , c , ∗ |
a Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
b Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou 310003, China
c The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou 310003, China
∗ Corresponding author at: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
E-mail address: shusenzheng@zju.edu.cn (S.-S. Zheng). |
|
|
|
|
Abstract Hepatocellular carcinoma (HCC) is a major health problem worldwide with high incidence and mortality rate [1,2] . Proper treatments for HCC mainly include surgical resection, transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA), and liver transplantation. However, many patients who are diagnosed with advanced HCC are not eligible for surgery, even the TACE and RFA does not necessarily have a good therapeutic effect. Until now, sorafenib is currently the first-line antitumor drug for the treatment of patients with advanced HCC.
|
|
|
|
|
|
|
|
|
2020, Vol. 19 
